Perspective Therapeutics, Inc. (New York Stock Exchange Arca:CATX)
| Market Cap | 289.11M-37.2% |
| Revenue (ttm) | 366.00K-44.5% |
| Net Income | -116.43M-26.7% |
| EPS | -1.56+92.0% |
| Shares Out | 114.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,199,081 |
| Open | 2.43 |
| Previous Close | 2.46 |
| Day's Range | 2.38 - 2.56 |
| 52-Week Range | 1.96 - 6.16 |
| Beta | 1.85 |
| Analysts | Buy |
| Price Target | 11.00(+333.93%) |
| Earnings Date | Nov 9, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About CATX
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CATX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CATX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CATX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CATX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CATX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CATX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CATX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $10.47M |
| IWMiShares Russell 2000 ETF | $6.64M |
| VXFVanguard Extended Market ETF | $3.12M |
| VTWOVanguard Russell 2000 ETF | $1.87M |
| IBBiShares Biotechnology ETF | $1.68M |
| DFASDimensional - US Small Cap ETF | $1.41M |
Estimated from each fund’s disclosed top holdings × AUM
CATX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CATX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score